A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer
Tetrathiomolybdate or TM, a drug developed for Wilson's Disease, removes copper from the
bloodstream. Copper is a key factor in angiogenesis (blood vessel growth)- a process that
occurs normally in the body but becomes uncontrolled in cancerous cells. Tetrathiomolybdate
essentially wages war against copper, which serves to choke off tumor growth. Realizing the
key role of copper in angiogenesis, researchers have begun exploring treatment with
Tetrathiomolybdate for different types of cancers. This clinical trial will evaluate the
effectiveness of Tetrathiomolybdate in the treatment of patients with hormone refractory
prostate cancer. Hormone refractory prostate cancer refers to advanced disease in which the
patient no longer responding to conventional hormonal treatment.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the time to progression and pattern of progression of prostate cancer in patients with androgen-independent prostate cancer treated with tetrathiomolybdate.
David C. Smith, MD
The University of Michigan Comprehensive Cancer Center
United States: Food and Drug Administration
|The University of Michigan Comprehensive Cancer Center||Ann Arbor, Michigan 48109|